BioCryst Pharmaceuticals,Inc. (BCRX)

[stockguard]

Some may think that the more Covid-19 candidate drug in the pipeline, the better, because in the end, the more likely some of them will eventually be approved. But I think this is not a correct thinking, because it is not about quantity, but quality.

As an example of behavior in the Covid race totally contrary to Sorrento we find the biotechnology BioCryst Pharmaceuticals (NASDAQ:BCRX). This company has been researching for several years with an antiviral "Galidesivir" that has shown high efficacy in “in vitro” tests against a wide range of different types of virus (filovirus, coronavirus, etc). Its safety profile is excellent according to a phase 1 trial conducted last year. And now it is immersed in trials with Covid patients, to verify its effectiveness in several hospitals in Brazil under the direction of one of the most prestigious Brazilian doctors specialized in infectious diseases; Dr. Esper Kallas. Results are expected before the end of this year 2020. Well, with this great efficacy and safety profile shown by Galidesivir, BioCryst has only reported one PR in the last 7 months: the one that reported the start of the trial last April. It is true that this lack of updating of the Galidesivir trial is weighing on BioCryst's share price, but I believe that in the end, shareholders will be rewarded for the long wait with the report of good results and the consequent appreciation of the share price.